<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>文悦思 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/wenyuesi/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Tue, 16 Jul 2024 02:45:46 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>文悦思 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国文拉法辛市场研究报告：2016-2020年CAGR约7.4%</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguowenlafaxinshichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Wed, 01 Sep 2021 08:53:19 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[5-羟色胺]]></category>
		<category><![CDATA[Effexor XR]]></category>
		<category><![CDATA[Serotonin–norepinephrine reuptake inhibitors]]></category>
		<category><![CDATA[SNRIs]]></category>
		<category><![CDATA[SNRI抑制剂]]></category>
		<category><![CDATA[倍特]]></category>
		<category><![CDATA[倍特药业]]></category>
		<category><![CDATA[博乐欣]]></category>
		<category><![CDATA[去甲肾上腺素再摄取抑制剂]]></category>
		<category><![CDATA[圣济乐]]></category>
		<category><![CDATA[圣济堂制药]]></category>
		<category><![CDATA[康弘药业]]></category>
		<category><![CDATA[怡诺思]]></category>
		<category><![CDATA[惠氏]]></category>
		<category><![CDATA[抑郁症]]></category>
		<category><![CDATA[抗抑郁药物]]></category>
		<category><![CDATA[文悦思]]></category>
		<category><![CDATA[文拉法辛]]></category>
		<category><![CDATA[文拉法辛区域分析]]></category>
		<category><![CDATA[文拉法辛市场份额]]></category>
		<category><![CDATA[文拉法辛市场竞争]]></category>
		<category><![CDATA[文拉法辛市场细分]]></category>
		<category><![CDATA[文拉法辛市场规模]]></category>
		<category><![CDATA[福元医药]]></category>
		<category><![CDATA[辉瑞]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=26759</guid>

					<description><![CDATA[文拉法辛是一种用来治疗重度抑郁症和其他精神障碍的抗抑郁药。2020中国市场文拉法辛销售额比2019年略有下降，达到约2.94亿元人民币（约4520万美元），2016-2020年CAGR约7.4%。预计随着COVID-19疫情在中国基本得到控制，2021-2025年中国文拉法辛市场将出现恢复性增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
